Crinetics Pharmaceuticals Inc [CRNX] stock is trading at $35.40, up 3.33%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRNX shares have gain 4.27% over the last week, with a monthly amount drifted -3.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On January 22, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $55 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $68 on March 06, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $50 as its price target on January 16, 2024. Jefferies started tracking with a Hold rating for this stock on December 21, 2023, and assigned it a price target of $35.
Crinetics Pharmaceuticals Inc [CRNX] stock has fluctuated between $31.84 and $62.53 over the past year. Currently, Wall Street analysts expect the stock to reach $91 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $35.40 at the most recent close of the market. An investor can expect a potential return of 157.06% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at -0.18% with Operating Profit Margin at -326.75%, Pretax Profit Margin comes in at -287.21%, and Net Profit Margin reading is -287.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.31 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.73 points at the first support level, and at 34.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.81, and for the 2nd resistance point, it is at 36.21.
Ratios To Look Out For
For context, Crinetics Pharmaceuticals Inc’s Current Ratio is 23.04. On the other hand, the Quick Ratio is 23.04, and the Cash Ratio is 4.43.
Transactions by insiders
Recent insider trading involved Pizzuti Dana, Chief Med and Dev Officer, that happened on Feb 03 ’25 when 5000.0 shares were sold. Officer, DANA J PIZZUTI completed a deal on Feb 03 ’25 to buy 5000.0 shares. Meanwhile, Chief Med and Dev Officer Pizzuti Dana sold 15000.0 shares on Jan 03 ’25.
